Twinbeech Capital LP Nektar Therapeutics Transaction History

Twinbeech Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $294,001 - $572,236	-92,745 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $385,819 - $1.27 Million	92,745 New	92,745 $500,000
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $170,851 - $246,276	-13,072 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $215,949 - $266,668	13,072 New	13,072 $224,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $171M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.